Abstract
The objectives of this study were to determine age- and gender-specific drug treatment prevalence rates for overactive bladder (OAB), and to compare resource use and costs among MCO members receiving drug treatment for OAB. Administrative claims data from seven affiliated health plans were analyzed for 8,661 members with a diagnosis or treatment indicative of OAB during 1998. Resource use and associated costs were analyzed over a four-month follow-up. In 1998, the prevalence of OAB among plan members was 1.1%. Of the patients with OAB, 71% did not receive pharmacotherapy. After multivariate analysis, treatment with tolterodine, oxybutynin, or other OAB treatment did not significantly affect the percent change in total per patient per month (PPPM) costs compared with the group not receiving a pharmacologic agent. Although the adjusted percent change in PPPM pharmacy costs was significantly higher within the tolterodine group, medical and total PPPM costs were not.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Benzhydryl Compounds / economics
-
Benzhydryl Compounds / therapeutic use
-
Cholinergic Antagonists / economics
-
Cholinergic Antagonists / therapeutic use
-
Comorbidity
-
Cost of Illness*
-
Cresols / economics
-
Cresols / therapeutic use
-
Female
-
Health Care Costs / statistics & numerical data*
-
Humans
-
Insurance Claim Reporting
-
Longitudinal Studies
-
Male
-
Managed Care Programs / economics*
-
Mandelic Acids / economics
-
Mandelic Acids / therapeutic use
-
Muscarinic Antagonists / economics
-
Muscarinic Antagonists / therapeutic use
-
Phenylpropanolamine*
-
Prevalence
-
Retrospective Studies
-
Tolterodine Tartrate
-
United States / epidemiology
-
Urinary Incontinence / complications
-
Urinary Incontinence / drug therapy*
-
Urinary Incontinence / economics*
-
Urinary Incontinence / epidemiology
Substances
-
Benzhydryl Compounds
-
Cholinergic Antagonists
-
Cresols
-
Mandelic Acids
-
Muscarinic Antagonists
-
Phenylpropanolamine
-
Tolterodine Tartrate
-
oxybutynin